Targanta Therapeutics

53 articles about Targanta Therapeutics

• The Medicines Company Completes Acquisition of Targanta Therapeutics

  2/26/2009

• The Medicines Company Announces Completion of Tender Offer for Shares of Targanta Therapeutics

  2/25/2009

• Targanta Therapeutics Enters into Memorandum of Understanding to Resolve Shareholder Lawsuit

  2/20/2009

• The Medicines Company Commences Tender Offer for All Outstanding Shares of Targanta Therapeutics

  1/27/2009

• The Medicines Company to Buy Targanta Therapeutics for $42 Million

  1/13/2009

• Targanta Therapeutics Announces Corporate Restructuring, Reduces 75% of Workforce

  12/19/2008

• Massachusetts Biotechnology Council, Inc. Release: 19 Biotech Companies Selected to Present at 10th Annual MassBio Investors Forum

  12/2/2008

• Targanta Therapeutics Announces Posting of Briefing Documents for Review of FDA Anti-Infective Drugs Advisory Committee Meeting for Oritavancin

  11/17/2008

• Shares of Targanta Therapeutics Surge on Positive FDA Review

  11/17/2008

• Targanta Therapeutics Reports Third-Quarter 2008 Financial Results

  11/12/2008

• Targanta Therapeutics to Present at November 2008 Investor Conferences

  11/5/2008

• Targanta Therapeutics Presents Preclinical In Vivo Data Demonstrating Activity of Oritavancin against Clostridium Difficile Infection

  10/27/2008

• Targanta Therapeutics Presents In Vitro Data Highlighting Oritavancin’s Potent Activity Against Gram-Positive Pathogens

  10/27/2008

• Targanta Therapeutics Presents Efficacy and Safety Data for Oritavancin for the Treatment of Gram-Positive Complicated Skin and Skin Structure Infections (cSSSI)

  10/27/2008

• Targanta Therapeutics Presents Data on Mechanisms That Underly Oritavancin’s Bactericidal Activity

  10/27/2008

• Targanta Therapeutics Releases Results from Phase 2 SIMPLIFI Study Evaluating Single or Infrequent Doses of Oritavancin

  10/22/2008

• Targanta Therapeutics Announces Review of Oritavancin at FDA Anti-Infective Drugs Advisory Committee Meeting

  10/15/2008

• Targanta Therapeutics to Present at Canaccord Adams Anti-Infectives Investment Conference

  9/12/2008

• Targanta Therapeutics Announces Positive Top-Line Results from Oritavancin Phase 2 SIMPLIFI Trial

  9/2/2008

• Targanta Therapeutics to Present at September 2008 Investor Conferences

  8/27/2008